Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

Wake, B, Hyde, C, Bryan, S, Barton, PM, Song, F, Fry-Smith, A and Davenport, C (2002) Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technology Assessment, 6 (3). pp. 1-85. ISSN 2046-4924

Full text not available from this repository. (Request a copy)

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User:	EPrints Services
Date Deposited:	25 Nov 2010 11:11
Last Modified:	24 Oct 2022 03:27
URI:	https://ueaeprints.uea.ac.uk/id/eprint/13890
DOI:

Actions (login required)

View Item